References
AHNERT-HILGER, G., DAUZENROTH, M. E., HABERMANN, E., HENSCHEN, A.,
KRIEGLSTEIN, K., MAULER, F. & WELLER, U. 1990. Chains and fragments of
tetanus toxin, and their contribution to toxicity. Journal de
Physiologie, 84, 229-236.
ALBRECHT, P., JANSEN, A., LEE, J.-I., MOLL, M., RINGELSTEIN, M.,
ROSENTHAL, D., BIGALKE, H., et al. 2019. High prevalence of
neutralizing antibodies after long-term botulinum neurotoxin therapy.Neurology, 92, e48-e54.
BAKRY, N., KAMATA, Y., SORENSEN, R. & SIMPSON, L. L. 1991. Tetanus
toxin and neuronal membranes: the relationship between binding and
toxicity. Journal of Pharmacology and Experimental Therapeutics,258, 613-619.
BEISE, J., HAHNEN, J., ANDERSEN-BECKH, B. & DREYER, F. 1994. Pore
formation by tetanus toxin, its chain and fragments in neuronal
membranes and evaluation of the underlying motifs in the structure of
the toxin molecule. Naunyn-Schmiedeberg’s Archives of
Pharmacology, 349, 66-73.
BENECKE, R. 2012. Clinical relevance of botulinum toxin immunogenicity.BioDrugs, 26, e1-e9.
BENJAFIELD, A. V., AYAS, N. T., EASTWOOD, P. R., HEINZER, R., IP, M. S.,
MORRELL, M. J., NUNEZ, C. M., et al. 2019. Estimation of the
global prevalence and burden of obstructive sleep apnoea: a
literature-based analysis. The Lancet Respiratory Medicine,7, 687-698.
BENN, S. C., AY, I., BASTIA, E., CHIAN, R.-J., CELIA, S. A., PEPINSKY,
R. B., et al. 2005. Tetanus toxin fragment C fusion facilitates
protein delivery to CNS neurons from cerebrospinal fluid in mice.Journal of Neurochemistry, 95, 1118-1131.
BERCSENYI, K., GIRIBALDI, F. & SCHIAVO, G. 2013. The elusive compass of
clostridial neurotoxins: Deciding when and where to go? Current
Topics in Microbiology and Immunology.
BORELLA-VENTURINI, M., FRASSON, C., PALUAN, F., DE NUZZO, D., DI MASI,
G., GIRALDO, M., et al. . 2017. Tetanus vaccination, antibody
persistence and decennial booster: a serosurvey of university students
and at-risk workers. Epidemiology and Infection, 145,1757-1762.
CALEO, M. & SCHIAVO, G. 2009. Central effects of tetanus and botulinum
neurotoxins. Toxicon, 54, 593-599.
CHEN, C., FU, Z., KIM, J.-J. P., BARBIERI, J. T. & BALDWIN, M. R. 2009.
Gangliosides as High Affinity Receptors for Tetanus Neurotoxin.The Journal of Biological Chemistry, 284, 26569-26577.
CHEN, S. 2012. Clinical uses of botulinum neurotoxins: current
indications, limitations and future developments. Toxins,4, 913-939.
CONDUIT, R., SASSE, A., HODGSON, W., TRINDER, J., VEASEY, S. & TUCKER,
A. 2007. A neurotoxinological approach to the treatment of obstructive
sleep apnoea. Sleep Medicine Reviews, 11, 361-375.
CONNAN, C. & POPOFF, M. R. 2017. Uptake of clostridial neurotoxins into
cells and dissemination. Uptake and Trafficking of Protein
Toxins. Springer.
DA SILVA ANTUNES, R., PAUL, S., SIDNEY, J., WEISKOPF, D., DAN, J. M.,
PHILLIPS, E., et al. 2017. Definition of human epitopes
recognized in tetanus toxoid and development of an assay strategy to
detect ex vivo tetanus CD4+ T cell responses. PloS one,12, e0169086.
DRESSLER, D. 2002. Clinical features of antibody-induced complete
secondary failure of botulinum toxin therapy. European neurology,48, 26-29.
DRESSLER, D. 2012. Clinical applications of botulinum toxin.Current Opinion in Microbiology, 15, 325-336.
DRESSLER, D. 2016. Botulinum toxin drugs: brief history and outlook.Journal of Neural Transmission, 123, 277-279.
EISEL, U., JARAUSCH, W., GORETZKI, K., HENSCHEN, A., ENGELS, J., WELLER,
U., et al. 1986a. Tetanus Toxin - Primary Structure, Expression
in Escherichia-Coli, and Homology with Botulinum Toxins. Embo
Journal, 5, 2495-2502.
EISEL, U., JARAUSCH, W., GORETZKI, K., HENSCHEN, A., ENGELS, J., WELLER,
U., et al . 1986b. Tetanus toxin: primary structure, expression in
E. coli, and homology with botulinum toxins. The EMBO journal,5, 2495-2502.
EISEL, U., REYNOLDS, K., RIDDICK, M., ZIMMER, A. & NIEMANN, H. 1993.
Tetanus toxin light chain expression in Sertoli cells of transgenic mice
causes alterations of the actin cytoskeleton and disrupts
spermatogenesis. The EMBO journal, 12, 3365-3372.
FIGUEIREDO, D. M., HALLEWELL, R. A., CHEN, L. L., FAIRWEATHER, N. F.,
DOUGAN, G., SAVITT, J. M., et al . 1997. Delivery of recombinant
tetanus-superoxide dismutase proteins to central nervous system neurons
by retrograde axonal transport. Experimental Neurology,145, 546-554.
FISHMAN, P. S., PARKS, D. A., BOWEN, T. & MATTHEWS, C. C. 2009.
Localized tetanus in immunized mice. Neurotoxicology,30, 697-701.
FISHMAN, P. S., SAVITT, J. M. & FARRAND, D. A. 1990. Enhanced CNS
uptake of systemically administered proteins through conjugation with
tetanus C-fragment. Journal of the Neurological Sciences,98, 311-325.
FRANCIS, J., BASTIA, E., MATTHEWS, C., PARKS, D., SCHWARZSCHILD, M.,
BROWN, R. & FISHMAN, P. 2004. Tetanus toxin fragment C as a vector to
enhance delivery of proteins to the CNS. Brain research,1011, 7-13.
FÜRCH, T., WITTMANN, C., WANG, W., FRANCO-LARA, E., JAHN, D. & DECKWER,
W. D. 2007. Effect of different carbon sources on central metabolic
fluxes and the recombinant production of a hydrolase from Thermobifida
fusca in Bacillus megaterium. Journal of Biotechnology,132, 385-394.
GRAMLICH, P. A., REMINGTON, M. P., AMIN, J., BETENBAUGH, M. J. &
FISHMAN, P. S. 2013. Tat-tetanus toxin fragment C: A novel protein
delivery vector and its use with photochemical internalization.Journal of Drug Targeting, 21, 662-674.
GRUMELLI, C., VERDERIO, C., POZZI, D., ROSSETTO, O., MONTECUCCO, C. &
MATTEOLI, M. 2005. Internalization and mechanism of action of
clostridial toxins in neurons. Neurotoxicology, 26,761-767.
HEFTER, H., ROSENTHAL, D., BIGALKE, H. & MOLL, M. 2019. Clinical
relevance of neutralizing antibodies in botulinum toxin long-term
treated still-responding patients with cervical dystonia.Therapeutic Advances in Neurological Disorders, 12,1756286419892078.
HELTING, T. B. & ZWISLER, O. 1977. Structure of tetanus toxin. I.
Breakdown of the toxin molecule and discrimination between polypeptide
fragments. Journal of Biological Chemistry, 252,187-193.
HESSE, S., KUTSCHENKO, A., BRYL, B., DEUTSCHLAND, M. & LIEBETANZ, D.
2020. Therapeutic effects of Tetanus neurotoxin in spinal cord injury: a
case series on four dogs. Spinal Cord Series and Cases,6, 1-10.
JOHNSON, E. A. 1999. Clostridial toxins as therapeutic agents: benefits
of nature’s most toxic proteins. Annu Rev Microbiol, 53,551-75.
KRIEGLSTEIN, K. G., HENSCHEN, A. H., WELLER, U. & HABERMANN, E. 1991.
Limited proteolysis of tetanus toxin: relation to activity and
identification of cleavage sites. European journal of
biochemistry, 202, 41-51.
LALLI, G., BOHNERT, S., DEINHARDT, K., VERASTEGUI, C. & SCHIAVO, G.
2003. The journey of tetanus and botulinum neurotoxins in neurons.Trends in Microbiology, 11, 431-437.
LAURENCE, D. & WEBSTER, R. 1963. Pathologic physiology, pharmacology,
and therapeutics of tetanus. Clinical Pharmacology &
Therapeutics, 4, 36-72.
LAVINDER, J. J., WINE, Y., GIESECKE, C., IPPOLITO, G. C., HORTON, A. P.,
LUNGU, O. I., et al . 2014. Identification and characterization of
the constituent human serum antibodies elicited by vaccination.Proceedings of the National Academy of Sciences of the United
States of America, 111, 2259-2264.
LUKIĆ, I., MARINKOVIĆ, E., FILIPOVIĆ, A., KRNJAJA, O., KOSANOVIĆ, D.,
INIĆ-KANADA, A. & STOJANOVIĆ, M. 2015. Key protection factors against
tetanus: Anti-tetanus toxin antibody affinity and its ability to prevent
tetanus toxin – ganglioside interaction. Toxicon, 103,135-144.
MASUYER, G., CONRAD, J. & STENMARK, P. 2017. The structure of the
tetanus toxin reveals pH‐mediated domain dynamics. EMBO reports,18, 1306-1317.
MASUYER, G., STANCOMBE, P., CHADDOCK, J. A. & ACHARYA, K. R. 2011.
Structures of engineered Clostridium botulinum neurotoxin derivatives.Acta Crystallographica Section F: Structural Biology and
Crystallization Communications, 67, 1466-1472.
MAYER, S., LAUMER, M., MACKENSEN, A., ANDREESEN, R. & KRAUSE, S. W.
2002. Analysis of the immune response against tetanus toxoid:
enumeration of specific T helper cells by the Elispot assay.Immunobiology, 205, 282-289.
MONHEIT, G. D. & PICKETT, A. 2017. AbobotulinumtoxinA: a 25-year
history. Aesthetic surgery journal, 37, S4-S11.
MORENO-IGOA, M., CALVO, A. C., PENAS, C., MANZANO, R., OLIVÁN, S.,
MUÑOZ, M. J., et al . 2010. Fragment C of tetanus toxin, more than
a carrier. Novel perspectives in non-viral ALS gene therapy.Journal of Molecular Medicine, 88, 297-308.
NAUMANN, M., BOO, L. M., ACKERMAN, A. H. & GALLAGHER, C. J. 2013.
Immunogenicity of botulinum toxins. Journal of neural
transmission, 120, 275-290.
OVESPIAN, S. V., BODEKER, M., O’LEARY, V. B., LAWRENCE, G. W. & OLIVER
DOLLY, J. 2015. Internalization and retrograde axonal trafficking of
tetanus toxin in motor neurons and trans-synaptic propagation at central
synapses exceed those of its C-terminal-binding fragments. Brain
Structure and Function, 220, 1825-1838.
PALERMO, A., WEBER, L. K., RENTSCHLER, S., ISSE, A., SEDLMAYR, M.,
HERBSTER, K., et al . 2017. Identification of a Tetanus Toxin
Specific Epitope in Single Amino Acid Resolution. Biotechnology
journal, 12, 1700197.
PATIL, S., WILLETT, O., THOMPKINS, T., HERMANN, R., RAMANATHAN, S.,
CORNETT, E. M., et al . 2016. Botulinum Toxin: Pharmacology and
Therapeutic Roles in Pain States. Current Pain and Headache
Reports, 20, 1-8.
PIRAZZINI, M., ROSSETTO, O., ELEOPRA, R. & MONTECUCCO, C. 2017.
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.Pharmacological Reviews, 69, 200-235.
PIRAZZINI, M., TEHRAN, D. A., LEKA, O., ZANETTI, G., ROSSETTO, O. &
MONTECUCCO, C. 2016. On the translocation of botulinum and tetanus
neurotoxins across the membrane of acidic intracellular compartments.Biochimica et Biophysica Acta (BBA) - Biomembranes,1858, 467-474.
POULAIN, B. & POPOFF, M. R. 2019. Why are botulinum
neurotoxin-producing bacteria so diverse and botulinum neurotoxins so
toxic? Toxins, 11, 34.
QAZI, O., SESARDIC, D., TIERNEY, R., SODERBACK, Z., CRANE, D., BOLGIANO,
B. & FAIRWEATHER, N. 2006. Reduction of the ganglioside binding
activity of the tetanus toxin HC fragment destroys immunogenicity:
implications for development of novel tetanus vaccines. Infect
Immun, 74, 4884-91.
RESTANI, L., GIRIBALDI, F., MANICH, M., BERCSENYI, K., MENENDEZ, G.,
ROSSETTO, O., et al. 2012. Botulinum Neurotoxins A and E Undergo
Retrograde Axonal Transport in Primary Motor Neurons. PLoS
Pathogens, 8.
ROSSETTO, O., PIRAZZINI, M., BOLOGNESE, P., RIGONI, M. & MONTECUCCO, C.
2011. An update on the mechanism of action of tetanus and botulinum
neurotoxins. Acta Chimica Slovenica, 58, 702-707.
SASSE, A., CONDUIT, R., RYAN, D., WOODS, W. & TUCKER, A. P. 2005. A
pharmacotherapy for obstructive sleep apnea. Sleep, 28,1015-1016.
SEITHER, R., LORETAN, C., DRIVER, K., MELLERSON, J. L., KNIGHTON, C. L.
& BLACK, C. L. 2019. Vaccination Coverage with Selected Vaccines and
Exemption Rates Among Children in Kindergarten—United States, 2018–19
School Year. Morbidity and Mortality Weekly Report, 68,905.
SHAPIRA, A. & BENHAR, I. 2010. Toxin-Based Therapeutic Approaches.Toxins, 2, 2519-2583.
STUDIER, F. W. 2005. Protein production by auto-induction in
high-density shaking cultures. Protein Expression and
Purification, 41, 207-234.
SUTTON, J. M., CHOW-WORN, O., SPAVEN, L., SILMAN, N. J., HALLIS, B. &
SHONE, C. C. 2001. Tyrosine-1290 of tetanus neurotoxin plays a key role
in its binding to gangliosides and functional binding to neurones.FEBS Letters, 493, 45-49.
TABAN, M. & PERRY, J. D. 2006. Pearls of botox usage.Oculoplastic Surgery, 4, 165-169.
TURTON, K., CHADDOCK, J. A. & ACHARYA, K. R. 2002. Botulinum and
tetanus neurotoxins: structure, function and therapeutic utility.Trends in Biochemical Sciences, 27, 552-558.
UMLAND, S. P., NAHREBNE, D. K., RAZAC, S., BEAVIS, A., PENNLINE, K. J.,
EGAN, R. W. & BILLAH, M. M. 1997. The inhibitory effects of topically
active glucocorticoids on IL-4, IL-5, and interferon-γ production by
cultured primary CD4+ T cells. Journal of allergy and clinical
immunology, 100, 511-519.
WANG, J., MENG, J., LAWRENCE, G. W., ZURAWSKI, T. H., SASSE, A.,et al . 2008. Novel chimeras of botulinum neurotoxins A and E
unveil contributions from the binding, translocation, and protease
domains to their functional characteristics. Journal of Biological
Chemistry, 283, 16993-17002.
WANG, J., ZURAWSKI, T. H., MENG, J., LAWRENCE, G. W., AOKI, K. R.,
WHEELER, L. & DOLLY, J. O. 2012. Novel chimeras of botulinum and
tetanus neurotoxins yield insights into their distinct sites of
neuroparalysis. FASEB Journal, 26, 5035-5048.
WILSON, P., SLADE, R., CURRIE, B. J., WALTON, S. F., HOLT, D. C.,
FISCHER, K., et al . 2003. Mechanisms for a novel immune evasion
strategy in the scabies mite Sarcoptes scabiei: a multigene family of
inactivated serine proteases. Journal of investigative
dermatology, 121, 1419-1424.
YOUSEFI, M., TAHMASEBI, F., YOUNESI, V., RAZAVI, A., KHOSHNOODI, J.,
BAYAT, A. A., et al . 2014. Characterization of neutralizing
monoclonal antibodies directed against tetanus toxin fragment C.Journal of Immunotoxicology, 11, 28-34.
YOUSEFI, M., YOUNESI, V., BAYAT, A. A., JADIDI-NIARAGH, F., ABBASI, E.,
RAZAVI, A., et al . 2016. Comparative human and mouse antibody
responses against tetanus toxin at clonal level. Journal of
Immunotoxicology, 13, 243-248.